Change in Health Behaviors Affect Quality of Life in Lymphoma Survivors
Baseline alcohol consumption was associated with a higher QOL score compared with never use of alcohol.
Hematologic Cancers
Adding Elotuzumab to Myeloma Treatment Regimens Does Not Improve Outcomes
Predictors of worse progression-free survival included ISS stage II, ISS stage III, and adverse cytogenetics.
How Can Lifestyle Factors Affect Myeloproliferative Neoplasms?
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
COVID-19: What Do We Know About Outcomes in Hematologic Malignancies?
Patients with hematologic malignancies are at an advanced risk when they also have COVID-19. What have some recent studies suggested about outcomes in patients who have both?
Myeloproliferative Neoplasms: How Do MPNs Affect Quality of Life?
As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Glofitamab Step-Up Dosing Efficacy Data Show High Complete Response Rates in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Researchers sought to determine whether glofitamab monotherapy would have high preliminary response rates in patients with R/R non-Hodgkin lymphoma.
Loncastuximab Tesirine Produces Durable Response in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether loncastuximab tesirine would have durable responses in heavily pretreated patients with R/R DLBCL.
Tafasitamab Plus Lenalidomide May Improve Overall Survival in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Rituximab Biosimilars Produce Comparable Outcomes in Diffuse Large B-Cell Lymphoma
Response and survival outcomes were similar with rituximab biosimilars and the originator.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...